实验噬菌体疗法对抗金黄色葡萄球菌引起的致命肺部脓毒症的小鼠。
Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice.
机构信息
Department of Microbiology and Infection, Faculty of Medicine, Kochi University, Kochi, Japan; Clinical Laboratory, Kochi University Hospital, Kochi, Japan.
Department of Microbiology and Infection, Faculty of Medicine, Kochi University, Kochi, Japan; Center for Innovative and Translational Medicine, Kochi University, Kochi, Japan.
出版信息
Microbes Infect. 2014 Jun;16(6):512-7. doi: 10.1016/j.micinf.2014.02.011. Epub 2014 Mar 12.
Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) can progress to lethal systemic infections. Bacteriophage (phage) therapy is expected to be effective against these critical infections. Previously, phage S13' was proposed as a potential therapeutic phage. We here examined phage treatment in a mouse model of lung-derived septicemia using phage S13'. Intraperitoneal phage administration at 6 h postinfection reduced the severity of infection and rescued the infected mice. Phage S13' can efficiently lyse hospital-acquired MRSA strains causing pneumonia-associated bacteremia in vitro. Thus, phage therapy may be a possible therapeutic intervention in staphylococcal lung-derived septicemia.
耐甲氧西林金黄色葡萄球菌（MRSA）引起的医院获得性呼吸道感染可进展为致命性全身感染。噬菌体（噬菌）治疗有望对这些严重感染有效。先前，噬菌体 S13'被提议作为一种潜在的治疗性噬菌体。在这里，我们使用噬菌体 S13'在肺部来源性败血症的小鼠模型中检查了噬菌体治疗。感染后 6 小时腹腔内给予噬菌体可降低感染的严重程度并拯救感染的小鼠。噬菌体 S13'可有效地裂解体外引起肺炎相关菌血症的医院获得性 MRSA 菌株。因此，噬菌体治疗可能是葡萄球菌肺部来源性败血症的一种潜在治疗干预措施。
Zotero 插件